Company intelligence / Profile preview

Vincere Biosciences

Cambridge, Massachusetts, United Statesvincerebio.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Vincere Biosciences develops small molecule therapeutics that enhance mitophagy by inhibiting USP30 or activating parkin to remove damaged mitochondria. This approach aims to slow or halt progression of Parkinson’s disease and other age-related conditions. Their lead molecules are preclinical but expected to reach clinical trials soon, supported by over $2.7 million in grants from NIH and Michael J Fox Foundation plus $6 million in investments.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

VB-08

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Daewoong Pharmaceutical (investment partner)HanAll Biopharma (investment partner)Healthspan CapitalQuadraScope

Beyond the preview

Go deeper on Vincere Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vincere Biosciences.

Explore the full profile